Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

  • End date
    Jan 14, 2026
  • participants needed
  • sponsor
Updated on 14 June 2021
For site information, send an email with site number to
Primary Contact
Investigational Site Number 8400005 (2.3 mi away) Contact
+8 other location


Primary Objectives:

Part 1 (dose finding, experimental substudies):

  • To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM.
  • Part 2 (expansion, experimental substudies):
  • To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone in terms of rate of very good partial response (VGPR) or better.

Secondary Objectives:

  • To assess the overall response rate (ORR) in each treatment arm.
  • To assess the clinical benefit rate (CBR) in each treatment arm.
  • To assess the duration of response (DOR) in each treatment arm.
  • To assess the time to first response (TT1R) in each treatment arm.
  • To assess the time to best response (TTBR) in each treatment arm.
  • To assess safety and tolerability in each treatment arm.
  • To assess progression free survival (PFS) in each treatment arm.
  • To assess overall survival (OS) in each treatment arm.
  • To evaluate the potential immunogenicity of isatuximab and novel agents when applicable.
  • To characterize the PK of isatuximab and novel agents.
  • To assess disease and treatment related symptoms, cancer and disease specific health-related quality of life, global impact of side effects and confirm/establish clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores.

-Substudy 1 (Control Arm):

  • To assess clinical outcomes assessments (COAs).
  • To assess the incidence of skeletal related events (SREs).
  • To assess the time to first occurrence of SRE.
  • To assess health care resource utilization related with SREs.

-Substudy 2:

  • To assess pain intensity related to skeletal related events (SREs).
  • To assess the incidence of SREs.
  • To assess the time to first occurrence of SRE.
  • To assess health care resource utilization related with SREs.

-Substudy 3:

  • To assess patient-reported visual functioning


Duration of study is approximately 28 months.

Condition Refractory Multiple Myeloma
Treatment Pomalidomide, Dexamethasone, isatuximab SAR650984, SAR439459, Belantamab mafodotin
Clinical Study IdentifierNCT04643002
Last Modified on14 June 2021


Yes No Not Sure

Inclusion Criteria

Participant must be 18 years of age inclusive or older
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Participants with relapsed or refractory MM who have received at least 3 prior lines of therapy for MM, including PIs and IMiDs or at least 2 prior lines if at least one of these lines consisted of 2 or more multiagent regimens (eg, Induction regimen with autologous stem cell transplant followed by maintenance)
RRMM with measurable disease
Serum M protein 0.5 g/dL measured using serum protein immunoelectrophoresis and/or
Urine M protein 200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain 10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65)
Men or woman or childbearing potential should agree to use contraception
Substudy 01, 02, 03: Anti-CD38 therapy nave or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy

Exclusion Criteria

Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma
Any anti-MM drug treatment within 14 days before randomization, including dexamethasone
Uncontrolled infection within 14 days prior to randomization
Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to randomization, eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0)
Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A
Uncontrolled or active hepatitis B virus (HBV) infection
The above information is not intended to contain all considerations relevant
Active hepatitis C virus (HCV) infection
Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease
to a patient's potential participation in a clinical trial
Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before randomization
Participants with a contraindication to treatment
Vaccination with a live vaccine 4 weeks before the start of the study
Hemoglobin <8 g/dL
Platelets <50 109/L
Absolute neutrophil count <1.5 109/L
Creatinine clearance <30 mL/min
Total bilirubin >1.5 ULN, except for known Gilbert syndrome in which direct bilirubin should be 2.5 ULN
Aspartate aminotransferase and/or alanine aminotransferase >3 ULN
Patients with grade 3 or 4 hypercalcemia
Substudy 01
Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide
Substudy 02
History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment
Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459
Prothrombin time or INR >1.5 upper limit of normal (ULN)
Substudy 03
Current corneal epithelial disease except mild punctate keratopathy
Patients who have received prior therapy with belantamab mafodotin
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note